Verition Fund Management LLC Sells 10,543 Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD)

Verition Fund Management LLC lowered its stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) by 22.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,166 shares of the company’s stock after selling 10,543 shares during the quarter. Verition Fund Management LLC owned approximately 0.10% of Lucid Diagnostics worth $55,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. LPL Financial LLC bought a new position in Lucid Diagnostics during the second quarter worth about $33,000. Bank of Montreal Can bought a new position in Lucid Diagnostics during the second quarter worth about $35,000. Millennium Management LLC bought a new position in Lucid Diagnostics during the second quarter worth about $55,000. State Street Corp boosted its position in Lucid Diagnostics by 24.4% during the first quarter. State Street Corp now owns 56,693 shares of the company’s stock worth $190,000 after purchasing an additional 11,121 shares during the period. Finally, Geneos Wealth Management Inc. bought a new position in Lucid Diagnostics during the first quarter worth about $209,000. Institutional investors own 5.89% of the company’s stock.

Analyst Upgrades and Downgrades

LUCD has been the subject of a number of research reports. BTIG Research cut their target price on shares of Lucid Diagnostics from $5.00 to $3.50 and set a “buy” rating for the company in a research report on Friday, November 18th. Needham & Company LLC lowered their price target on shares of Lucid Diagnostics from $4.25 to $3.10 and set a “buy” rating on the stock in a report on Tuesday, November 15th.

Lucid Diagnostics Trading Down 6.1 %

Shares of Lucid Diagnostics stock opened at $1.55 on Friday. Lucid Diagnostics Inc. has a 12-month low of $1.11 and a 12-month high of $3.66. The company has a market cap of $60.62 million, a price-to-earnings ratio of -1.05 and a beta of 1.99. The company’s 50-day moving average price is $1.34 and its 200-day moving average price is $1.67.

About Lucid Diagnostics

(Get Rating)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.